Recent Advances in the Synthesis of Xanthines: A Short Review

Table 1

Patent filed for xanthine derivatives in last twenty years (2002–2020).

S. No.	Patent application number	Year of filing	Applicant name	Patent office	Compound	Category
1	AU 200521 958-B2 [6]	2005	Boehringer Ingelheim International GmbH	Australian		DPP-IV inhibitor
2	CA 02873524 [7]	2007	Boehringer Ingelheim International GmbH	Canadian	1-[(4-methyl-quinazolin-2-yl)methyl]-3-7-(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl) xanthine	DPP-IV inhibitor
3	EP 2058311A2 [8]	2003	Boehringer Ingelheim International GmbH and Co.	European patent office		DPP-IV inhibitor
4	DE 6020050 00 986T2 [9]	2005	Loreal Paris	Deutsches patent under Markenamt	—	Obesity
5	EP 1368349 B1 [10]	2002	Boehringer Ingelheim International GmbH and Co.	Europian		DPP-IV
6	EP 1515972 B1 [11]	2003	F.Hoffman-La Roche AG 4070 Basel (CH)	Europian		Type-II diabetes
7	EP 1599477 B1 [12]	2004	F.Hoffman-La Roche AG 4070 Basel (CH)	Europian		PEPCK inhibitors
8	EP 1689748 B1 [13]	2004	Boehringer Ingelheim International GmbH	Europian		Diabetes
9	ES 2401128 T3 [14]	2006	GlaxoSmithKline LLC	Spain		Agonist of HM74 A
10	US 7696212 B2 [15]	2010	Boehringer Ingelheim International GmbH and Co. KG	United States		DPP-IV inhibitor
11	US 7838529 B2 [16]	2010	Boehringer Ingelheim International GmbH, Ingelheimam Rhein (DE)	United States		Type-2 diabetes mellitus, antiobesity.
12	US 7879864 B2 [17]	2011	Sanofi-Aventis Deutschland GmbH, Frankfurt am main (DE)	United States		DPP-IV inhibitor
13	US 9221821 B2 [18]	2015	Forest Laboratories Holdings Limited, Hamilton (BM)	United States		-
14	US 10202383 B2 [19]	2019	Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)	United States		DPP-IV
15	US 10214530 B2 [20]	2019	Max-Delbruck-Centrum Fur Molekulare Medizin, Berlin (De), Forschungs-Verbund-Berlin-E. V., Berlin (De)	United States		Serotonin based disease
16	US 201111 8464 [21]	2009	Ing-Jun Chen Linya District (TW)	United States		Anticancer